Clinical Trial Search

Primary: Time to Resolution of Acute Respiratory Viral Infection (ARVI) Symptoms (ARVI, Confirmed by Polymerase Chain Reaction (PCR)). — 3.3; 4.4 day — p=0.0003

Primary: Pharmacokinetics (PK): Maximum Concentration (Cmax) of Tirzepatide — 647; 524 nanograms per milliliter (ng/mL)

Primary: Percent of Participants With Correct Responses for Healthy Lifestyle Behavior Knowledge Survey Questions. — 33; 44; 56; 33 percentage of participants

Primary: Number of Patients With a Treatment-related Immunologic Effect — 6 Participants

Primary: Change in Viral Load in the Nasopharynx Over the Course of COVID-19 Infection — .116; .071; .118 Log10 copies/mL/days

Primary: The Number of Days Free From Diaper Dermatitis — 4.065; 4.274 Days

Primary: Validity of Portion Size at Estimating Energy Intake in Laboratory Conditions — 742.9; 659.3 kcal

Primary: Reduction Ratio (RR) of Lambda Free Light Chains (λ FLC) — 36.02; 19.03 Reduction Ratio (%) — p=<0.0001

Primary: Change in Dopamine Transporter Imaging — 4.6; -15.9 % change in arbitrary intensity units

Primary: Mean CNC Word Scores — 71.0; 68.4 Percent Correct — p=.768

Primary: Change in Number of Nighttime Awakenings Per Night as Measured by Parent Sleep Diary — -0.88 awakenings per night — p=0.000393

Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) in PART-1: SAD — 2; 1; 1; 0 Participants

Primary: Change From Baseline in Foreign Body Sensation, Burning/Stinging, Itching, Pain, Stick Feeling, Blurred Vision, Photophobia and Total Ocular Tolerability Score (VAS)…

Primary: Incidence of Adverse Events During 6 Weeks of Treatment — 88.5; 72.0 percentage of subjects

Primary: Objective Response Rates (RECIST 1.1) — 42.4 Percentage of participants